Microfluidic Platforms for Exosome Engineering: Scalable Therapeutics for Cancer Immunotherapy and Infectious Diseases
International Journal of Molecular Sciences · 15.07.2026 · 27 (14) · 6298
DOI: 10.3390/ijms27146298 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.07.2026. Verfasst von Minyoung Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Technology, Kangwon National University, Chuncheon 24341, Republic of Korea. Hauptthemen laut MEDLINE: Exosomes, Immunotherapy, Neoplasms, Microfluidics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Health and Welfare.
Abstract (Originalsprache)
Extracellular vesicles (EVs), particularly small EVs or exosomes, are promising cell-free therapeutics with superior biocompatibility and intrinsic targeting for synthetic nanoparticles. However, conventional bulk preparation methods suffer from low yield, poor reproducibility, and structural instability. Microfluidic technologies resolve these issues by enabling precise, automated, and low-shear fluidic manipulation. This mini-review highlights recent advances in microfluidic-engineered exosomes for cancer immunotherapy and infectious diseases. We evaluate critical microfluidic strategies for isolation, surface engineering, and cargo loading, contrasting platforms like ExoArc, acoustofluidics, cellular nanoporation, and electroporation. Particular emphasis is placed on complex modalities, including immune cell-derived exosomes (IEX), neo-antigen presentation, chimeric antigen receptor (CAR)-derived exosomes, and targeted siRNA delivery networks. Crucially, we analyze the technological disconnect between analytical microfluidic scales and massive therapeutic manufacturing volumes, addressing how physical forces risk damaging conformationally sensitive surface proteins (e.g., CAR scFv). Finally, we outline future perspectives, including high-throughput 3D-multiplexed networks, stimulus-responsive scarless elution, and integrated “sample-to-therapy” circuits. Guided by the MISEV2023 guidelines, this review frames the path toward standardized, clinical-scale engineering of multi-functional, cell-free immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Republic of Korea.
- School of Biopharmaceutical and Medical Sciences, Sungshin Women's University, 55 Dobong-ro 76 ga-gil, Gangbuk-gu, Seoul 01133, Republic of Korea.
ORCID-Profile: Kwangmin Park, Kyung-A Hyun, Anbazhagan Sathiyaseelan
Förderung
- National Research Foundation of Korea
- Ministry of Health and Welfare
Zitieren
APA
Lee, M., Park, K., Kim, J., Hyun, K. A., Sathiyaseelan, A., & Park, S. (2026). Microfluidic Platforms for Exosome Engineering: Scalable Therapeutics for Cancer Immunotherapy and Infectious Diseases. International Journal of Molecular Sciences, 27(14), 6298. https://doi.org/10.3390/ijms27146298
Vancouver
Lee M, Park K, Kim J, Hyun KA, Sathiyaseelan A, Park S. Microfluidic Platforms for Exosome Engineering: Scalable Therapeutics for Cancer Immunotherapy and Infectious Diseases. International Journal of Molecular Sciences. 2026;27(14):6298. doi:10.3390/ijms27146298
BibTeX
@article{Lee2026,
author = {Lee, Minyoung and Park, Kwangmin and Kim, Jungho and Hyun, Kyung-A and Sathiyaseelan, Anbazhagan and Park, Sunyoung},
title = {Microfluidic Platforms for Exosome Engineering: Scalable Therapeutics for Cancer Immunotherapy and Infectious Diseases},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {14},
pages = {6298},
doi = {10.3390/ijms27146298}
}
EUVIMED